ImPact Biotech Reports Promising Early Results for Padeliporfin VTP in Pancreatic Cancer, Eyes Strategic Partnerships
Key Insights
ImPact Biotech (search) reported that 66% of patients with unresectable locally advanced pancreatic ductal adenocarcinoma (search) became eligible for surgery following treatment with Padeliporfin VTP at the lowest light dose in a Phase 1 trial.
The vascular targeted photodynamic therapy demonstrated a well-tolerated safety profile with no complications related to arterial injury, thrombosis, or other VTP-related morbidity in the initial cohort.
The company is pursuing strategic partnerships for its low-grade upper tract urothelial carcinoma (search) program while advancing the pancreatic cancer indication, which represents a large market opportunity with potential for accelerated regulatory pathway.
ImPact Biotech (search) has reported encouraging preliminary results from its Phase 1 study of Padeliporfin vascular targeted photodynamic therapy (VTP) in patients with unresectable locally advanced pancreatic ductal adenocarcinoma (search) (LA-PDAC), with two-thirds of treated patients becoming eligible for surgery following treatment at the lowest light dose.
The clinical-stage biotechnology company presented data showing that 2 of 3 patients (66%) successfully underwent surgery following Padeliporfin VTP treatment with a low light dose of 200 mW/cm, with the third patient remaining ineligible for surgery due to mesenteric tumor spread unrelated to the VTP procedure. These results were presented at the Society of Interventional Radiology (SIR) 2026 Annual Meeting in Toronto.
Safety Profile Remains Consistent
The therapy demonstrated a well-tolerated safety profile consistent with previous clinical studies across multiple indications. No complications were observed related to arterial injury, thrombosis, ischemia, or other VTP-related morbidity. Additionally, no select treatment-related adverse effects (sTRAE) or dose-limiting toxicities (DLT) were observed in any patients in the initial cohort.
"At the lowest dose, Padeliporfin VTP has so far not only demonstrated a well-tolerated profile – consistent with the robust body of data generated across indications – but, importantly, also shown promising signs of clinical efficacy highlighting its potential to convert patients with unresectable tumors to become eligible for surgery," said Eyal Morag, M.D., Chief Medical Officer of ImPact Biotech (search).
Addressing Significant Unmet Need
Pancreatic ductal adenocarcinoma (search) represents the third-leading cause of cancer deaths, with a five-year survival rate of approximately 10% – the lowest among all solid tumors. At diagnosis, only about 20% of patients have resectable or borderline resectable disease, while the remaining 80% present with unresectable tumors that are either locally advanced or have distant metastases.
The Phase 1 LA-PDAC trial is a two-part dose-escalation and expansion study evaluating Padeliporfin VTP in patients with vascular encasement deeming them ineligible for surgical resection. The primary objective in Part A is to assess safety and determine the optimal light dose to progress into Part B for further evaluation, with secondary objectives including assessment of preliminary efficacy as patients are evaluated for potential pancreaticoduodenectomy (Whipple procedure).
Strategic Focus and Partnership Opportunities
ImPact has completed patient enrollment in the second cohort of the Phase 1 dose-escalation study and expects to report additional data throughout 2026. Subject to future discussions with the U.S. Food and Drug Administration (FDA), the company believes the program may have potential to move directly into a registrational study.
"Given PDAC's large addressable market and potential for an efficient development path forward, this program represents a compelling near-term opportunity for ImPact," said Barak Palatchi, Chief Executive Officer of ImPact Biotech (search). "The significant platform potential demonstrated by Padeliporfin VTP across several indications has enabled us to strategically pursue opportunities with the greatest potential for patient impact and long-term value."
Dual Program Strategy
While advancing the pancreatic cancer program, ImPact is simultaneously pursuing strategic partnering opportunities for the commercialization of its low-grade upper tract urothelial carcinoma (search) (UTUC) program. The company recently presented updated safety and efficacy data from the ENLIGHTED Phase 3 trial at the European Association of Urology's 41st Annual Congress in March 2026, with Padeliporfin VTP continuing to demonstrate a potentially best-in-class profile for treatment of low-grade UTUC.
Topline data from the Phase 3 ENLIGHTED trial in low-grade UTUC and submission of a new drug application (NDA) for Padeliporfin VTP to the FDA are anticipated in 2026. The company will present updated data from both programs at the American Urological Association (AUA) Annual Meeting in May 2026 and the American Society of Clinical Oncology (ASCO) Annual Meeting.
Technology Platform
Padeliporfin VTP is a minimally invasive drug-device combination that delivers non-thermal laser light via optical fibers to locally activate Padeliporfin in the tumor microenvironment for selective ablation of unresectable solid tumors. The novel VTP platform is currently being evaluated across multiple indications, with earlier stage studies ongoing or planned in high-grade UTUC and non-small cell lung cancer (search) (NSCLC).